ChIP-Atlas 2025 update: 10-year anniversary of a data-mining platform for exploring epigenomic landscape
Clinical Snapshot
PICO Framework
| P — Population | Researchers and bioinformaticians working with public epigenomic profiling datasets (ChIP-seq, ATAC-seq, DNase-seq, Bisulfite-seq) across multiple model organisms including humans |
| I — Intervention | ChIP-Atlas 2025 platform update — incorporating experiment-level quality control frameworks and parametric gene set enrichment analysis (GSEA) modules operating on continuous RNA-seq count tables |
| C — Comparator | Prior ChIP-Atlas platform versions and existing epigenomic data-mining tools; implicit comparison to threshold-dependent discrete gene list approaches for enrichment analysis |
| O — Outcomes | Platform utility, data reliability assessment capability, flexibility of enrichment analysis, coverage of publicly available epigenomic experiments (>460,000 experiments), and advancement of quantitative epigenomic landscape exploration |
Bottom Line
ChIP-Atlas 2025 is a mature, freely accessible epigenomic data-mining platform that has now integrated over 460,000 publicly deposited experiments spanning ChIP-seq, ATAC-seq, DNase-seq, and Bisulfite-seq assays. The 2025 update delivers two substantive improvements: an experiment-level quality control framework that allows users to assess data reliability before analysis, and a parametric gene set enrichment analysis module that operates on continuous RNA-seq count data, circumventing the well-recognised limitations of arbitrary threshold-based gene list generation. These are genuine methodological advances for the field. However, this paper is a descriptive platform update report — it sits at CEBM Level 5 and provides no formal benchmarking, statistical validation of the QC framework, or comparative performance data against competing platforms such as Cistrome or ReMap. For senior clinician-researchers, ChIP-Atlas remains a valuable hypothesis-generation tool for exploring transcription factor binding, chromatin accessibility, and DNA methylation landscapes. Findings derived from the platform require independent experimental validation before informing clinical or translational decisions. Australian genomics researchers will find the platform immediately accessible and relevant to NHMRC-funded epigenomics programmes.
Key Findings
P Value: Not reported — no hypothesis testing performed
Effect Size: Not reported — no comparative effect sizes provided; quantitative claim limited to data volume expansion to >460,000 experiments
Primary Outcome: Successful implementation of two major platform enhancements: (1) an experiment-level quality control framework embedded in every experiment page, and (2) a parametric GSEA module enabling enrichment analysis from continuous RNA-seq count tables without threshold-defined gene lists
Nnt Or Sensitivity: Not applicable — no NNT, sensitivity, specificity, or hazard ratios reported; tool development paper without clinical outcome metrics
Confidence Interval: Not reported — no confidence intervals provided; this is a descriptive platform update paper
Clinical Application
High feasibility for research use — the platform is freely accessible via web browser at https://chip-atlas.org/ with no installation required. The parametric GSEA module reduces the technical barrier of threshold selection, making the tool more accessible to researchers without deep bioinformatics expertise. However, meaningful clinical translation requires substantial downstream experimental validation. ChIP-Atlas is directly relevant to Australian epigenomics and genomic medicine research, including programs supported by the Australian Genomics Health Alliance, AGHA, and NHMRC-funded epigenomics projects. Australian researchers at institutions such as the Garvan Institute, WEHI, QIMR Berghofer, and university-based genomics centres can utilise this platform for hypothesis generation in cancer epigenomics, immunological disorders, and developmental diseases. There is no PBS or TGA regulatory relevance as this is a research informatics tool, not a therapeutic or diagnostic product. RACGP guidelines do not currently address epigenomic data-mining platforms. The platform's utility aligns with Australia's National Health Genomics Policy Framework objectives for advancing genomic research infrastructure. Basic scientists, translational researchers, and bioinformaticians investigating gene regulatory mechanisms, epigenetic modifications, chromatin accessibility, and DNA methylation patterns. Indirectly applicable to clinician-researchers in oncology, immunology, developmental biology, and precision medicine who require epigenomic context for interpreting genomic variants or therapeutic targets.
Abstract
ChIP-Atlas (https://chip-atlas.org/) is a data-mining platform that systematically processes and integrates public epigenomic profiling data, including ChIP-seq, ATAC-seq, DNase-seq, and Bisulfite-seq, together with curated sample metadata, currently encompassing >460 000 experiments across multiple model organisms. In this 2025 update, an experiment-level quality control framework was embedded in every experiment page, enabling intuitive assessment of data reliability and representativeness. In addition, a parametric analysis of gene set enrichment-based module was implemented, allowing enrichment analysis directly from continuous RNA-seq count tables without relying on threshold-defined, discrete gene lists, thereby helping elucidate underlying gene regulatory mechanisms. Combined with sustained data expansion, these updates advance ChIP-Atlas into a more quantitative and flexible platform for exploring the epigenomic landscape in multicellular organisms, marking its 10th anniversary.
References
- 1.Zou, Z., Ohta, T., Kasukawa, T., & Oki, S. (2026). ChIP-Atlas 2025 update: 10-year anniversary of a data-mining platform for exploring epigenomic landscape. Nucleic Acids Research. https://doi.org/10.1038/s41467-024-54441-5
Related Research
The American journal of pathology
An Integrated Machine Learning and Genomic Framework for Precise Detection of Gastric Cancer
3 Aug 2026
Genome biology
IDEAL-Age: an interpretable deep learning framework for single-cell resolution profiling of immunological aging
27 July 2026
Nucleic acids research
FABIAN-variant 2026: improved prediction of the effects of DNA variants on transcription factor binding
13 July 2026
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service